Negotiations database

Indication:

Pompe disease

Indication:

reducing the risk of developing skeletal-related events in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumors; treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severemorbidity; and treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate

Indication:

treatment of postmenopausal women with osteoporosis at high risk for fracture; treatment to increase bone mass in men with osteoporosis at high risk for fracture; treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy, who are at high risk for fracture; treatment to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for nonmetastatic breast cancer; and treatment to increase bone mass for the treatment and prevention of glucocorticoid- induced osteoporosis in women and men at high risk for fracture

Indication:

Treatment of opioid-induced constipation (OIC) in adult patients with cancer and non-cancer pain who have had an inadequate response to laxative(s).

Indication:

for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by a validated test, and who have received one or two prior systemic treatment regimens

Indication:

As an adjunct to standard of care in adults with heart failure with left ventricular ejection fraction (LVEF) ≥ 40% to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits.

Indication:

As an adjunct to diet for the treatment of adults with familial chylomicronemia syndrome (FCS) to reduce triglyceride levels.

Indication:

Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older

Indication:

Friedreich's ataxia

Indication:

for the stimulation of follicular development in women, as part of an assisted procreation activity, administered concomitantly with follitropin